Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Unknown primary cancer]

H Furue1

  • 1Teikyo University, Kawasaki, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 17, 1998
PubMed
Summary
This summary is machine-generated.

Unknown primary cancers (UPCs) are diverse tumors, with some subgroups responding to treatment. Identifying these treatable unknown primary cancers requires further molecular characterization to improve patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.

Oncogene·2010
Same author

Responses to 5-HT in morphologically identified neurons in the rat substantia gelatinosa in vitro.

Neuroscience·2009
Same author

Action of neuropeptide Y on nociceptive transmission in substantia gelatinosa of the adult rat spinal dorsal horn.

Neuroscience·2005
Same author

[Anti-nociceptive effect of calcitonin on chronic pain associated with osteoporosis].

Clinical calcium·2005
Same author

Functional reorganization of the spinal pain pathways in developmental and pathological conditions.

Novartis Foundation symposium·2004
Same author

Analysis of receptive fields revealed by in vivo patch-clamp recordings from dorsal horn neurons and in situ intracellular recordings from dorsal root ganglion neurons.

Life sciences·2004
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Cancer Research

Context:

  • Unknown primary cancers (UPCs) represent a heterogeneous group of tumors.
  • Most patients with UPCs exhibit poor response to systemic therapy and have unfavorable survival durations.

Purpose:

  • To define subgroups of unknown primary cancers that are responsive to treatment.
  • To identify patients with unknown primary cancers who may benefit from specific therapeutic strategies.
  • To highlight the need for further research into the molecular characteristics of UPCs.

Summary:

  • UPCs are diverse, but specific subgroups, defined by organ site and histology (e.g., cervical lymph node squamous cell carcinoma, axillary adenocarcinoma in females, peritoneal carcinomatosis in females, poorly differentiated or undifferentiated carcinomas, and poorly differentiated neuroendocrine carcinomas), show treatment responsiveness.

Related Experiment Videos

  • Despite identification of some treatable subgroups, the origin and biology of most responsive UPCs remain unclear.
  • A significant proportion of UPC patients do not respond to current therapies, necessitating further investigation.

    • Impact:

    • Improved identification of treatable unknown primary cancer subgroups.
    • Enhanced understanding of UPC biology and metastatic processes.
    • Potential for developing targeted therapies for previously intractable cancers.